Allakos Inc Asset Resilience Ratio
Allakos Inc asset resilience ratio. Allakos Inc (ALLK) has an Asset Resilience Ratio of 52.08% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ALLK cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Allakos Inc (2018–2024)
Asset resilience ratio of Allakos Inc from 2018 to 2024. This chart shows how Allakos Inc's Asset Resilience Ratio has changed over time. Read Allakos Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Allakos Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Allakos Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $31.01 Million | 52.08% |
| Total Liquid Assets | $31.01 Million | 52.08% |
Asset Resilience Insights
- Very High Liquidity: Allakos Inc maintains exceptional liquid asset reserves at 52.08% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Allakos Inc Industry Peers by Asset Resilience Ratio
Compare Allakos Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Allakos Inc Asset Resilience Ratio by Year (2018–2024)
Allakos Inc asset resilience ratio by year from 2018 to 2024. The table below shows the annual Asset Resilience Ratio data for Allakos Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 65.29% | $63.07 Million | $96.60 Million | +22.45pp |
| 2023-12-31 | 42.84% | $104.35 Million | $243.61 Million | -7.00pp |
| 2022-12-31 | 49.83% | $192.57 Million | $386.42 Million | -0.91pp |
| 2021-12-31 | 50.75% | $271.42 Million | $534.82 Million | -12.04pp |
| 2020-12-31 | 62.79% | $451.82 Million | $719.62 Million | -25.73pp |
| 2019-12-31 | 88.52% | $457.53 Million | $516.89 Million | +12.57pp |
| 2018-12-31 | 75.94% | $145.25 Million | $191.26 Million | -- |
About Allakos Inc
As of May 15, 2025, operates as a subsidiary of Concentra Biosciences, LLC.